Unicycive Therapeutics (UNCY) Income from Continuing Operations (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Income from Continuing Operations data on file, last reported at 19905000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 153.15% year-over-year to 19905000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53139000.0 (down 70.82% YoY) and the FY2025 annual result came in at 54174000.0, down 7.22% from the prior year.
• Income from Continuing Operations fell to 19905000.0 in Q1 2026, from 6444000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 3806000.0 in Q1 2022 to a low of 233257000.0 in Q1 2023.
• A 5-year average of 29387764.71 and a median of 7863000.0 in 2025 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 6028.67% — and 2024, when it jumped 96.04%.
• Tracing UNCY's Income from Continuing Operations over 5 years: stood at 5328000.0 in 2022, then declined by 16.22% to 6192000.0 in 2023, then slumped by 43.86% to 8908000.0 in 2024, then climbed by 27.66% to 6444000.0 in 2025, then slumped by 208.89% to 19905000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 19905000.0 (Q1 2026), 6444000.0 (Q4 2025), and 14572000.0 (Q3 2025), per Business Quant data.